More About the Program:
There has been significant recent progress in the management of patients with chronic hepatitis C (CHC), and
cure rates continue to rise. However, before the millions of Americans with CHC can receive the full benefits of
treatment, they must be diagnosed and appropriately treated. Physicians therefore need to learn how to identify
those with CHC and provide optimal treatment for each patient, including an understanding of HCV genotypes,
treatment schedules, drug-drug interactions, and the management of adverse effects, such as rash and anemia.
This CME activity places an emphasis on updating treatment algorithms with new treatment
options and reviewing new agents in development that impact treatment decisions made today.
Back to Top
Health care providers who care for patients with CHC, including gastroenterologists, hepatologists, infectious
disease specialists, internal medicine specialists and family practice physicians, nurse practitioners, physician
assistants, and nurses. There are no fees or prerequisites.
Back to Top
After attending this activity, the participant will demonstrate the ability to:
Utilize patient characteristics and desires to appropriately and effectively use antiviral drugs in patients with CHC;
Utilize all information regarding drug adverse events, drug pharmacokinetics and likely patient adherence to provide
each patient with a treatment regimen for CHC that is likely to achieve antiviral success and avoid morbidity and
mortality;
Integrate newer antiviral drugs into current treatment algorithms for the management of CHC patients;
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
Supported by an independent educational grant from Merck & Co., Inc.
|
Mark Sulkowski, MD |
Paul Y. Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Division of Gastroenterology and Hepatology Indiana University School of Medicine Indianapolis, Indiana |
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Back to Top
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Back to Top
American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
Physician assistants may receive a maximum of 2.0 hours of Category 1 credit for completing this program.
It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course handout materials.
The Johns Hopkins University School of Medicine fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.
